Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Malaria Vaccine Phase IB Clinical Trial: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants

NCT01081847 is registered in ClinicalTrials.gov with Malaria Vaccine and Drug Development Center as lead sponsor.

NCT NCT01081847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01081847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Malaria Vaccine Phase IB Clinical Trial: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Lead sponsor
Malaria Vaccine and Drug Development Center
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2005
Completion date
April 30, 2006
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, vivax